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The extracellular bilayers which mediate the epider-
mal permeability barrier are enriched in ceramides, 
free fatty acids, and cholesterol. Yet, the epidermal 
lamellar body, the source of these lipids, is enriched 
in a more polar mixture; i.e., glucosylceramides and 
phospholipids, which it delivers to the stratum cor-
neum (SC) interstices. Whereas the extracellular pro-
cessing of glucosylceramides to cerami des has been 
shown to be required for barrier homeostasis, the 
requirement for phospholipid degradation to free 
fatty acids is not yet established. In tIlls study, we 
ascertained that topical applications of two chemi-
cally unrelated inhibitors of secretory phospholipase 
A2 (PLA2), bromphenacyl bromide and MJ-33, pro-
duced a progressive perturbation in barrier function 
in intact murine skin, first appearing at 5 d, preceded 
by the development of epidermal hyperplasia. More-
over, the defect in barrier homeostasis could be 
reversed by topical co-applications of the nonessen-
tial fatty acid, and of palmitic acid, but not by 
linoleic acid, both products of phospholipid catabo-
A major fun ction of the epide rmis is to generate a barrier that prevents excess wat.er loss. T his perme-ability barri er is localized within the extraceUular. lipid-enriched domains of the stratum corneum (SC ) (re viewed in [1-3]). T he lipid compositio n of the SC 
differs greatly from the lipids present ill the Ilucleated layers of the 
epide rn1is. consisting pt'imarily of a nonpolar mixture o f cho les-
terol . ceramides. and free fatty ;tcids (reviewed in [4.5]). T hese 
lipids are derived primarily from the exocytosis of lame llar body-
det:ived contents from stratum granulosllll1 (SG) cells [1 .3,6]. Since 
the major lipids in lameUar bodies comprise a relatively polar 
mix ture of cholesterol. g lu cosylcenll1lides. and phospho lipids 
[3.7,8]. secreted lamellar body lipid precursors must be metabolized 
within the extrace llul ar spaces into more hydroph obic lipid prod-
ucts durin g barrier formation . 
Manuscript rece ived March 24, 1995; rev ised July 17. 1995; accepted fo r 
publicatio n Aug ust 22, 1995. 
.Reprint requests to : Dr. Peter M. Elias, Dermato logy Service (190) . 
Veterans Aff., irs Medica l Center, 4150 C lement Street, Sail Francisco. CA 
94121. 
Abbreviatio ns: SC. srraturn corncurn; SG, stratulIl granulosum : PLA1 • 
phospho lipase A2 ; 13P13. bro mo phenacyl bromide; TEWL. tra nsepidermal 
water loss : I-IPT LC, high-perfo rmance thill laye r chro matograph y. 
lism. Furthermore, the barrier abnormality was ac-
companied by a reduction in free fatty acid levels in 
the stratum corneum, while phospholipid levels re-
mained unchanged. These biochemical alterations 
were accompanied by the appearance of immature, 
incompletely processed lamellar body-derived mem-
branes in the SC interstices, and depletion of histo-
chemically detectable neutral lipid. Both the abnor-
malities and the epidermal hyperplasia were reversed 
by co-applications of palmitic acid (but not linoleic 
acid) with either inhibitor. These results demonstrate 
that processing of phospholipids to nonessential free 
fatty acids, by a yet-to-be-identified extracellular 
phospholipase, is required for the maintenance of 
barrier homeostasis in intact skin. Furthermore, our 
studies show that the barrier abnormalities induced 
by the PLA2 inhibitors are due to a failure to generate 
free fatty acids rather than to phospholipid accumu-
lation. KeJ' lI1ol'ds: epidel'l1Ial lipids/lwl'I'ie,' fll1lctioll/epide,'-
mal "ltrastYllctUJ'e. J bwest Del'matol 106:57-63, 1996 
Lamellar bodies also contain an an 'ay of hydrolytic enzym es, 
including sphingomyelin ase , triacylglycerol hydro lase, J3-glucosi-
dases. phospholipase A, acid phosphatase. and certain proteases 
[7 .9], w hich are co-secreted with the lipids into the extraceUular 
spaces of the SC [1 0-12] . Recent studies have shown that certain 
of these enzymes process the relative ly po lar lipids derived fro l11 
lamell ar bodies , within the extT3cellular spa ces, in to the m ore 
nOli po lar mixt ure that predominates in th e SC. For exampl e . 
con version of g lucosylceramides to ceramides by J3-glucocerebro-
sidase is essential for normal barrie r hom eostasis: instead of the 
compact, m embrane bilayer uni t stru ctures n o rmally present in the 
intercellu.lar domains of the SC, immature and loosely o rgani zed 
m embrane structures appear wh en J3-glucocerebrosidase activity is 
inhibi ted or de leted [1 3,14]. 
Very recent studies have shown tha t blockade of the conv ersion 
of phospholipids to free fatty acids by inhibi tion of phospholipase 
A2 (PLAz) act ivi ty w ith the topica l application of either of two 
chemi cally unrelated sui cide inhibitors o f secretory PLAz• brol11o-
phenacyl bro mide (BPB) or MJ33, acu te ly alters barrier ho m eosta-
sis. A single topica l application of either o f these in hibi tors delays 
barrier repair followin g acute barrier disruption with aceto ne [1 5]. 
M oreover, this delay jn barrier recovery is associated w ith an 
increase in phospholipids and a decrease in free fatry acids within 
inhibi tor-trea ted SC, without significa nt e ffects o n fatty acid SY11 -
0022-202X/96/S10 .S0 • Copyri ght © 1996 b y The Society for Investiga tive Dcrmato lop;y, Inc. 
57 
58 MAN ET ilL 
t h es is. Furthermore, blockad e of th e conve rsion of phosph ol ipids to 
fi'ce fatty ac ids a lso results in thc appearance of abnormal. cxtra-
cellul ar m e mbrane bilayer structurcs within t h e SC in te rstices. Most 
importantly. th e fun ctional , biochemical, and structural abnorma l-
iti es that res ult fi'om the acute inhjbi tion of PLA2 activity could b e 
normali zed by a singl e co-applica tion of palmitic acid , but not 
lin o le ic acid, a product of phospho lipid ca taboli sm, suggesting th at 
a d e fici en cy of nonessen t ial free fatty acids accoun ts for th ese 
abnormali ties [15]. Finally, the abili ty of palmitic acid to ovelTide 
inhibitor blockade corre lated with the formatio n of mature extra-
cellula r m e mbrane hilayer structures in isolated, inhibitor-treated 
stratum corneum [1 5]. Thus, in th e setting of acu te b a rrier repai r , 
the conversion of phospholipids to free fatty ac ids plays a c rucial 
ro le in harrie r homeostas is . In th e prese n t study, we dete rmined 
wheth er sustained inhibi tion of extra cellul a r PLAz activ ity by 
rcpeated appli ca tion s of th e inhibi tors to otherwise intac t skin 
wo uld produce alterations in SC structure, function , and lipid 
composition . In thi s model , as in the parall e l acu te model, extra-
cellula r processing of secreted phospholipids in to nonesse n tia l fatty 
acids appears to be requil-ed for barrie r h omeostasis. 
MATETUALS AND METHODS 
Materials Mal c hairl ess mice (J-IrlHr) , 8 -1 2 wk o ld . were purchased 
from Simonsen Laboratories (G il roy, CA), and fed Pln;na mouse diet and 
water lid /i/,i(",,,. Acetone and propylene glyco l were from Fisher Scien tific 
(Fa irlane, NJ), while 131'13 and pa lmi tic acid were from Sigma C hemical Co. 
(St. Lo ui s, MO). O ne-hcxadecyl-3-t.-ifl uroethylglyce ro- sn-2-phospllo-
mcthano l (MJ33) was synthesized as described previously [1 6]. L-li gh-
performance thin layer c1u-omatography (I-IPTLC) sili ca-gel pre-coated 
plates were purchased from Brin kmann Instruments (Westbury, NY). 
I~uthenium tetroxide and osmium tetroxide we re from Polysc ience, Inc. 
(Warrington . PAl. 
Experimental Protocols Animals were treated topica ll y once daily w ith 
BPB (1 mg/ml ; 20 ILg tota l), M]3 3 (1 mg/ l11l; 2U I-',g totil l) in a propylene 
glyco i:ethanol vehicle (7:3 vo l), o r vehicle alone to a 5- to (,_cm2 area on 
the bilcks of norm,,1 hairless mice. These doses have been shown both to be 
nontoxic in acetone-treated murine skin fj 5], and to inhibit secreto ry PLA2 
activity selectively in several oth er tiss ues and cell types [1 T\. In other 
experiments, a parallel gro up of inhibito r-trcil ted animals also simulta-
neously received co-applications of palmitic acid or lino leic acid ( 10 mg/ ml ; 
20 ILg total) . Barrier function was determined by mcasurement of tra nsepi-
de rmal water loss (TEW"L) with a Meeco electrolytic water ana lyzer 
(Meeco. Warrington. PAl, every other day prio,' to the next app lication of 
inhibitor. The raw fun ctional (bta were converted to g/m2/ h. and ex-
pressed as mean :t SEM" 
Lipid BiochClnistry Seven days after vehi cle, npl3 o r MJ33 treatment, 
cpidcfllla\ sheets 'were sepa rated f'j'oln the dcrnli s by heat se paration , as 
described previously [18, ·19\. Ep idermal sheets then were incubated for 2 h 
at 37°C in a O.54~, trypsin so lu tion ill c:llc iurn- and J11agn cs iUlTl-frcc 
phosphate-b l.lft"e red sa li ne (tryps in cont<lining less than 2 ng of PLA2 activity 
per lOO ILg tryps in . After incubations, the samples were gently vortex cd to 
rClllOVC residual nucleated ce ll s, the rCI11ailljng intact SC sheet was was hed 
with disti ll ed wate r four times, and sample weigh ts were obtained afte r the 
SC sheets wcre b lotted dry with Kil11wipes . Total li pids were extracted frol11 
the SC. using Bligh-Dyer so lvents, fo llowed by fractionation and quantita-
tion by HPTLC, as described brieRy \20]: Two microgra l11 s of lipid was 
applied o nto plates for neutra l lipid analysis. w ith both 20 o r 100 ILg utili zed 
for polar li pid analysis. Both to generate standard curves. and to identify the 
n",jo r species. 0.2 to 1.0 ILg of a polar lipid standard and 0. 1. 2 to ·1.0 ILg of 
a ne utra l lipid standard were applied in parallel. Neutra l lipids were 
fnlctionated by developing the plates in petro leum ether:diethyl cther:acetic 
acid (80:20:1. vo l) , as described previously l20].1'01ar lipids we re deve loped 
to 35 and 55 111111 in chlo roform:ethyl acetatc:ethy-mcthylketone:2-p ropa-
1101:ethanol:mcth"n ol:glacia l acetic acid:hexyl acetate (34 :4:4:6:20:28:4:1. 
vo l). and tben to 70 mill in choroform:ethyl acctate:2-p ropanol:ethano l: 
methano l:H20 (46:4:4:6:6:20:2H:6, vol), and then to the top of the plate in 
chlo roforrn:ll1ethano l:acetone (80: 10: ·10, vo l). The plates were painted with 
a charring solution , charred. and the ll scanned dcnsitolTlCtrica ll y. and the 
lipid fractions were q uantitated by using CATS 11 software, as described in 
detai l previously. 
Light and F luorescence Microscopy Biopsy samples. taken o n day O. 
4. and 7 fro III both ve hi cle- and inhibitor-treated animals, we re embedded 
in paraffin and stained w ith hc rll otoxylin-cos in fo llowed b y v isuali zati o n 
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Figure L Repeated Applications of PLA2 Inhibitors Disrupt Bar-
rier Function. Following ~ive daily applications of e ither of the two PLA, 
inhibito rs (20 /log/day) to intact sk in . barrier function, as assessed by TEWL, 
begins to deteriorate. In contrast, the veh.icle alone does not disrup t the 
barrie r. Err"r bars, SEM; n = 5 separate sites on three animals in each groUP' 
with a Leitz Ortholux 11 microscope. The number of nucleated ce ll layers ill 
10 cross-sections, chosetl at rand 0l11 fronl each gro up, was assessed .IS a 
measure of hyperplasia. Fresh biopsy sa mples were also ohtained in parallel 
for lipid histochemistry and snap-fi'ozell immediately in liq uid ni trogen, 
Five-micromete r fl-ozen sections were sta ined with nil e red for depiction of 
po lar and neutral lip id loca li zation \21], and exami ned by fluorescence 
microscopy in the Le itz microscope equipped tor epiRuo rescence. 
Electron Microscopy Seven da ys after applications of either vehicle or 
PLA2 inhibitors, biopsy sample ' we re taken from treated areas, minced (0 
0.5 mm~ , fixed in nlOdifled Karnovsky's fIxative overnight . w"s hed in 0.1 
M c"codylate buft"er. and post-fixed in either 0.2'1., ruthenium tetrOXide 
(JtuO.I) o r 111., OSI11iUI11 tetroxide. cO llt:linin g O.SIXI pot:1SS iUlll fcrrocya nidc. 
as described in detai l prev ious ly l221. U ltrathin sections we re examjned ill 
a Zeiss ·IOA electron microscope opera ted "t 60 kV. 
Statistical Analysis Statistical signifi cances wc re determined using " 
two-tai led Student's t test. 
RESULTS 
PLAz Inhibitors Disrupt Barrier Function in Intact Skin 
Qur initial stud ies determine d w h eth er repeated topica l app li cations 
of o ne o r both PLA2 inllibitors would d isrupt barrier function in 
in tact skjn. No significan t ch ange in barri e r fu n ction , m easured HS 
TEWL rates, occurs in anim als treated with vehi cle a lo n e for 7 d 
(Fig 1). In contrast, TEWL in c reases signif"icantly after five con-
secutive daily appli cations of e ither BPI3 or MJ 33 (Fig 1). More-
over , th c extent of barrier disru ption progresses with time, so thal 
by 7 d TEWL rates a re m arked ly abnormal in both BPB- and 
MJ33-treated animals. T hu s, repeated applications of either of the 
two, chemica lly unre lated PLA 2 inhibi tors perturb barrie r ho-
meostasis in in tact skin . 
The Ability of PLA2 Inhibitions to Disrupt the Barrier Is 
Due to Enzyme Inhibition To determin e whether the effects 
of th e phospholipase A2 inhibi tors on barrier funct ion can be 
attributed sp ecifically to inhibi t ion of th e conversion of phosphO-
lipids to free fatty acids , we n ext co-applied a product of phospho-
lipid ca tabolism, palmitic acid, with each of th e inhibi tors. As 
sh ow n in F ig 2 , th e abnormali ty in barrier funct ion indu ced by 
e ithe r BPB o r M]33 is prevented b y sim ultaneous co-applications of 
palmita te. In con t ra st, co-applications oflill o le ic ac id h ;Jd no e ffect ; 
i.e_, they did not pre vent or d e lay e m ergen ce of th e barrier 
abnormality (data n ot sh own ). These data indicate first, that the 
di sruption of barrier fUll ctio n seen in BPB- o r MJ3 3- treated an im als 
ca n be attribu ted to th e impaired con vers ion of phospholipids to 
nonessential free fatty ac ids, ra ther than to nonspec ific toxi c e ffects 
of these compou nds. In addition, th ese studies demonstrate a 
requirement for n onessentia l fj-ee fatty acids, an end produ c t of 
phospholipid cataboli sm, for barrier h o m eostasis in intact skill. 
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Figure 2. Co applications of Palmitic Acid Block Emergence of the 
Barrier Abnormality. Data shown arc for seven daily applications of 
inhibitor ± palmitic acid (20 J.Lg/ day) to int"ct skin. Each inhibitor alone 
again produces a highly signifi cant barrier abnormali ty (c ,f. , F ig 1). which 
is reduced towards veh.icle levels significantly by co-applications of palmitic 
acid (PA ); i.e., differences of inhibitor + PA vcrws inhibitor are significant 
at < 0.01 and < 0.05 for BPB and MJ33 , respectively. Both BPB + PA and 
MJ33 + PA water loss rates are not signifi cantly different from vehicle 
alone. Error 1101'S, SEM; n = 5 sites on three animals in each group. 
PLA2 Inhibitors Alter SC Lipid Content \X1e next assessed 
whether topical applications of BPB and MJ33 alter the lipid 
content of the SC. As shown in Fig 3, 7 d of treatment with BPB 
resulted in an approximately 50°Ic, reduction in free fatty acid 
content in the SC (p < 0.001). In con trast, the quantities of free 
sterols, phospholipids, and sphingolipids are not changed signi fi -
cantly by BPB administration . A comparable decrease in free fatty 
acids is seen with MJ33 treatment (Table I); phospholipid content 
remains unaffected (data not shown). T hese results indicate that 
repeated applications of either of the two , chemically unrelated 
PLA2 inhibitors to intact skin result in a m arked decrease in SC free 
fatty acid content. 
PLA2 Inhibitors Alter the Delivery of Stainable Neutral 
Lipids to the SC Interstices To determine w hether inhibition 
of PLA2 alters the generation of f"ee fatty acids within the SC 
interstices, we next visualized the distribution of neutral lipids with 
ni le red (Fig 4A; a major portion of nile red-stainable lipids that 
exhibit green-gol.d fluorescence in the SC are free fatty acids) [1]. 
In vehicle-treated animals (7 d), bright gold fluorescence is ob-
served in the SC in a membrane pattern, indicating the presence of 
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Figure 3. BPB Applications Deplete the Stratlllu Corneum of Free 
Fatty Acids. Data shown arc fi'om animals treated with scven dail y 
app lications of llPll (20 J.Lg;lday) to intact skin (1'1 = 6 in vchicle and n = 7 
in BPB groups). Stratum corncum is obtaincd by heat separation (60°C, 60 
sec) fo llowed by trypsi nization . Total lipids wcre extracted with Bligh-Dyer 
solvents, and fra ctionated by quantitative HPTLC . W hereas fi·cc fatty acids 
content is reduced signi ficantly, other 1l1'~ior lipid classes, includillg phos-
pholipids, arc not sign itlcantl y affected (c.f .. Table I). Em'r bars, SEM. 
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Table I. Effect of MJ33 on Stratum Corneum Neutral 
Lipid Content" 
Fraction 
(J.Lg/mg SC) Vehicle Sign MJ33 
Neutral lipids 
Free sterols 6.32 :t 0.49 NS 5.48 :t 0.46 
Free fatty acids 18.64 :t 1.26 < 0.001 10.96 :t 1.05 
Sterol esters 8.53 :t 2.68 NS 3.45 :t 0.60 
Tota l 33.48 :t 3.63 < 0.01 19.89 :t 1.82 
" Hairless mice wcrc treated with either MJ33 (20 /-Lg/ d) or vehicle for 7 d. Stratum 
corneum sheets -were harvested by heat sc par;]tion followed by trypsinization . To t.., I 
lipids were eXTracted ","ith Bligh-Dyer .-;olvc.nts, fr',1criorJ:ltcd by HPTLC. alld ql.l :mri-
t:lred by photodensitomctry. Results ~l rc mean :!: SEM; 11 = 6 for vehicle ;lI1d n = 5 for 
MJ33 groupS. NS, not significant. 
abundant neutral lipids (Fig 4B), In contrast, in both BPB- and 
MJ33-treated samples, nil e red-stainable material is markedly re-
duced in the SC, and no membrane pattern is observed (Fig 4C,D). 
Moreover, co-applications of palmitic acid with either of the 
inhibitors normalized the pattern of lipid staining in the SC (Fig 
4E,F). T hese findings support the biochemical results, by providing 
further evidence that treatment with PLA2 inhibitors decreases the 
content of stainable neutral lipid of the SC. In addition, they show 
that co-application of palmitic acid with the PLA2 inhibitors 
normalizes the pattern of stainable neutral lipid in the SC. 
PLAz Inhibition Results in Epidermal Hyperplasia The 
effects ofBPB and MJ33 on cutaneous morphology is shown in Fig 
5A-E. In comparison with vehicle- treated skin (Fig 5E), at 7 d, 
BPB- and MJ33-treated skin displays a marked increase in the 
number of nucleated cell layers (Fig 5A,B) , fr0111 an average of 
three to four in vehicle- treated samples to six to seven in inhibitor-
treated samples (hyperplasia is also evident in Fig 4C,D). T he 
hyperplasia can be ascribed to PLA2 inhibition, because : (i) it is 
induced by both of the chemically unrelated inhibitors; and (ii) its 
development is prevented by topical co-applications of palmitic 
acid (Fig 5C,D; reversal of hyperplasia also is seen in Fig 4E,F) . 
Moreover, the hyperplasia cannot be ascribed to barrier disruption , 
because it appears at 4 d (Fig 5F, G), pl'ior to development of the 
barrier abnorma lity (c. f., F ig 1). Furthermore, development of 
hyperpl as ia is blocked by co-application of palmitate, even pl;or to 
development of the barrier abnormality (Fig 4H). Finally, in 
con~rast to the results with palmitic acid, the emergence of the 
barrier abnormality is not blocked by co-applications of linoleic 
acid (LA) (5 d TEWL: 2.14 ± 0.38 liS 2.46 ± 0.21mg/cm 2 / h , BPB 
alone IICl'S IiS BPB + LA, respectively). These results demonstrate 
first, that epidermal hyperplas ia occurs as a consequence of inhibi-
tion of epidermal PLA2 activity. Second, since epiderm.al hyperpla-
sia appears before emergence of the balTier abnormality, hyperpla-
sia cannot be attribu ted to prior barrier disruption. Th.ird, the 
nonessential fatty acid, palmitic acid, prevents the emergence of 
both the barrier abnormality and hyperplasia. 
PLAz Inhibitors Alter SC Extracellular Membrane Structure 
In order to determine whether the bioch emical abnormalities 
described above are responsible for the bauier abnormality, we 
next examined SC lamellar membrane structure in inhibitor- Iler.ws 
vehicle-treated skin. As in previous studies (e.g., [13 ,15,20,23]) , 
vehicl e applications alone to intact skin alter n either the number 
nor the appearance of lamellar bodies in SG cells (not shown). 
Moreover, n either the quantities of secreted lamellar materia l at the 
SG-SC interface, nor the appearance of extracellular membrane 
bilayers in the SC interstices are altered (not shown). Furthermore, 
inhibitor-treated animals do not exhibit abnorma lities in either the 
nucleated layers of the epidermis or in lamellar body structure and 
number (not shown; see [15]) . In BPB-treated animals, unproc-
essed, secreted lamellar body-derived membranes persist for sev-
era l cell layers above th e SG-SC interface (Fig 6A). In contrast, 
60 MAN ET IlL T H E JOU R.NAL O F INV EST IGATIVE DER.MATOLOGY 
Figure 4. Both PLA2 Inhibitors Deplete the Stratum Corneum of Stainable Neutral Lipids. Nile red flu o rescence of stratum corneum lipids in 
5-JLm froze n secti ons. A ) Untreated control hairless mo use epidermis (N) shows bri ght strainin g for ncutrallipids ill stratum co rnc um (a rrows). B) After seven 
dail y applications of vehicle (1/) alone. ne utra l lipid staining in stratum corneum is moderately decreased (nrnJ IIJs; dasiles, basem cnt m embranc). After sevcn 
applicati o ns (20 JLg daily) of e ither BPB (C ) or MJ33 (0), ncutralli p id sta ining is markedly diminished-to-absent (OpC II a fro ",,.; "' positive sebaceous lipid staining 
for compa rison). Epidcrmal hype rplasia is evident after treatment w ith both inhib itors. Dail y app li cations (20 JLg/day) ofpa hnitic acid (PA ) (with either BPB 
IB ] or i\Jlj3J [F]) restore ncutral lip id staining to stratUJ11 co rneum (so lid arrow s) and reduce cpidermal hyperpl asia considerab ly. A-F) X ·I .(JOO. 
normal basic uni t structures usually appear in th e first or second 
interspace above th e SG-SC juncti on in vehicle-treated contro ls 
(c.f., Fig 6B). M o reover , the absen ce of lam ellar unit stru ctures 
results in a loose, irregular a rrangem ent of membranous material 
throughout the SC iJJte rst ices ill inhibito r- treated samp les (Fig 6A). 
MJ 33 gavc similar results (data not shown) . FinalIy, co-applications 
o f palmiti c acid with e ith er of the inhibi tors n o rm alizes me mbrane 
bilayer structure in the SC (Fig 6C [BPE + PAl and d ata not shown 
[MJ33 + PAJ). T hese results dem onstrate that the redu ction in free 
fatty acids, resulting from susta in ed inhibi tion of PLA 2 , produces 
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Figure 5. Both PLA2 Inhibitors Produce Epidermal Hyperplasia. Six-micro meter paraffin-embedded sections). After seven appli catio ns (20 J.Lg daily) 
of either BPB (A) or MJ33 (B). prominent epidermal hyperplasia is evidenr in compari son to ve hicle ( I/)-treated controls (E) B,.,,( /.I ,'(s in all fig ures, w id th 
of nucleated layers. Daily co-applicatio ns (20 J.Lg) of pa lmitic ac id (PA) w ith either BPB (C) o r MJ33 (D) largely reverse the epidermal hyperplasia. Similar 
resu lts arc seen at 4 d , prior to the emergence of a banier abno rmali ty (F: Vehicle: C: BPB; H: BPB + PAl . A-H) X750 (hematoxybn and eos in). 
abnormal m embrane structures in the SC in te rstices, which in turn 
resu lt in the barrier abnorm ali ty. 
DISCUSSION 
T he lipid compositio n of the SC differs from the lipid composition 
of lamellar bodies, the organell e which de livers lipid to the SC 
extracellular spaces. Whereas lamellar bod ies contain predomi-
nantiy cholesterol, glucosy1ceramides, and phospholipids [7]. the 
lipids in the SC extracellular spaces comprise mainly cho lesterol. 
ceramides, and free fatty acids [4,5 J. T hese chemical differen ces 
sugges t that extracellular degradation of po lar lipid precursors into 
m ore nonpolar lipid products occurs durin g the fo rmati o n of the 
lipid-enriched bi layers in the SC interstices. Mo reover, in additi on 
to delivering lipids, lam ellar bod y exocytosi s deposits hydro lytic 
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FigulOc 6 . T he Extracellular Membrane Structural Abnormalities Produced by PLA. Inhibitors Are Due to Fatty Acid Depletion. After seven 
dai ly app lications ofllPS or MJ33 (20 fLg dail y each) abnormal intercellular lameUar structures appear w.ithin the intercel lular spaces at all leve ls of the stratum \ 
corneum . A rrows in A, membrane structures in EPl3-treated, mid-stratum corneum; i.e. between the third and fo urth layer of the stratum corneum (MJ33 
data not showlJ). T hese .Itructllres replace the no rmal lo1l1le lJar bi layers seen in vehicl e-treated con tro ls (B . arro,"s) . Co-applications of palmitic acid (20 Ilg 
da il y) with either EPE or M]33 normalize the appearance of interce llular lamellae (C, arrowheads, EPl3 ; MJ33 plus palmitic acid not shown). AJ I arc ruthenium 
tetroxide p ost-fixed . A) X95 ,OOO; B) X 115,000; C) X62,SOO. 
enzym es, such as glycosidases and a variety oflipa ses, w ithin the SC 
in te rstices [9-1 2]. T hus, lam ellar bodies appear c<Ipa ble of deliver-
in g not o nly the lipids, but also the hydrolytic enzymes req uired for 
the extracellul ar processing of secreted polar lipids into the more 
no npolar species that form the lamellar bilaye r uni t structures 
respo nsible fo r barri er fun ction [3]. Whereas the co-loca li zation 
studies described above provide strong c irclll1lstantial evide nce for 
extra cellular processing, direct evidence foi' th ese m e tabolic trans-
formation s, and for their impoI·tan ce for barrier homeostasis, has 
o nly recentl y been forth coming. For exa mple, barrier disruption 
regulates both the activity and the mRNA levels of f3-glu cocere-
brosidase [24] , the en zyme whi'ch catlyzcs the conversion of 
. glu cosylceramides to ceramides. Mo reover, inhibition of epiderm al 
f3-glucocerebrosidase activity both inhibits barrier repair [24], and 
leads to abnormal barrier fu nction in intact ski n [13]. The biochem-
ical bas is fo r the barri er abnorma Li ty with susta ined inhibition of 
f3-glucocerebrosidase appears to be an accumulation of glucosylce-
ram ides (1 3J, which results in e longated but incOJJ1pletely pmcessed 
membran e structures [13,24]. T he morphology of these immature 
m echanism s is reminiscen t of normal structures seen in mu cosal 
epithelia (25,26] and m arine cetaceans [27], w here glycosylceram-
ides accumul ate due to an apparent de fi ciency in endogenous 
f3-g lycosidase activity [28]. 
Recently, w e showed th at inhibition ofPLA 2 activ ity after acute 
perturbations of the barrier also results in an inhibition of barrier 
repair [1 5]. In this acute model, the ban'ier abnormality also was 
shown to resul t ti'om the f.1 ilure to generate £i'ce fatty acids £i'om 
phospho lipids, and , as ill the present studies, the abnormali ty was 
attributable to the acc umulation of abnorma l "immature" mem-
brane stru ctures in the SC interstices. T he aim of the present study 
was to determine whether the susta in ed inhibiti on of PLA2 activity 
by the repeated topica l application of two different inhibitors to 
norm al, intact skin would alter barricr homeostasis . T he present 
study demonstrates that inhibiti on ofPLA2 by either o f two suicide 
inhibi tors, BPB or MJ3 3 , produccs progressive elevations in 
TEWL, indicative of impai red barricr fun ction. Moreover, the 
defect in barrier fun ctio n is accompanied by al te rations in the 
structure o f thc lame llar bilayers in thc SC inte rstices, comparable 
to those seen after a sin gle app li ca tion of the inhibitor to ace ton e-
treated skin , ·15J. T hc compact lamell ar bi layers that arc present in 
normal stra tum corneum are replaced by irregular, loosely arranged 
m embranes in the SC interstices. T hat this abnormali ty ill structure 
and function is due to impaired degradation of phospho lipids to 
fatty acids is shown first, by lipid bioche mica l anal yses, which 
revealed a striking decrease in SC fre e fatty acid content, compa-
rable to the decrease found with inhibi to r treatmen t in the acute 
model [15] . Moreover, in the latter m odel, we showed furth er that 
the decrease in fi'ee fatty acids could not be attributed to a toxic 
effect of th e inhibitors o n fatty acid synthesis [15J . Second, nile red, 
a fl uorescent dye th at stains neutral lipi ds [20], w hich largely 
comprise fi'ee fat ty acids in the SC [4], de monstrates reduced 
stainin g in b oth BPB- and MJ33-trcated SC. Prior studies have 
show n that nile red flu orescence is an indicato r of vari ations in SC 
fatty acid content [29]. Lastly, and most importantly, co-applica-
tions of th e no nessential fatty acid , palmitic acid, prevents dle 
de leterio us e ffects of BPB and MJ33 on SC structure and barrier 
functi on, as in the acute model. The last fi nding indica te s that the 
structura l and fUllc tional abnormalities induced by the PLA 2 inhib- • 
itors can be attribu ted to inhibitio n of the con ve rsion of phospho-
lipids to £i'ee f.,tty acids, with a resultant defi cie ncy of non-cssential 
free fatty acids, rather than to nonspecifIC toxic e ffects. W hereas 
prior studies have shown that f.1tty acids are required for barrier 
function [29], these studies m ore specifically demonstra te a specific 
requircment for nonessential free fatty acids. 
It is noteworth y that in thi s m ode l, as in the previolls ly described 
acute Illodel (15], palmitic acid , but not linoleic acid, is able to 
override PLA 2 inhibition . T his constellation of findin gs suggest 
that epidermal phospho lipids, destined for barrier functio n , may be 
atypical; i. e ., rather than being enriched in unsaturated f.1tt)' acids ill 
the sn-2 position , as is usual, w here these m o iet ies are poised for 
eicosanoid generation [,/7, 30,31 ], they in stead may contain satu-
rated fatty acids at the sn-2 positi on. Certainly, the fi'ee fatty acids 
of stratum corne um , whi ch derive largely, if no t entirely, from 
phosph o lipid ca tabolism (3-5] , contain a pilu city of lin o leic acid; 
instead, palmitic and oleic acids predominate [3 2] . In this respe t, 
the phospholipids in thc epidermal lam ellal' body may resemble the 
lam ellar bodies of the lung type II cell , which conta in primarily 
dipa lmitoylphosphatidylcholine (revie wed in [33]). Furth er studies 
are needed to cl arify the special characteri stics, if any, of lamellar 
body phospholipids. 
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Previo Ll s studies by o ur labo ra to ry and others have de mo nstrated 
that topically applied free fatty acids can affect barrier fun ctio n b y 
two distinct m echanism s: (i) ei ther directl y by interactin g w ithin the 
SC [1 5,34] ; o r (ii) indi rectly by al tering the ratios of lipids in 
secreted lam ell<1r bodies [35]. In these studi es, a direct correction by 
the fatty acid of the SC membrane abn o rmali ties, produced b y 
either BPB o r MJ 33, would expl ain how palmi tic acid could 
norm alize the barrier in isolated stra tum corn eum [1 5] , witho ut the 
requirem en t fo r prio r intracellular processin g and assembly in to 
nascen t lam e llar bo di es [36] . In addi tion, in tracellul ar p rocess ing is 
not likely to be o perative, because the prio r assembly of free fatty 
acids in to phosph o lipids, fo ll owed b y PLA 2-med iated gene ration of 
free fatty acids, wo uld be blocked by the two inhibi to rs. A third 
possibili ty, name ly that palmitic acid could either dilute or in te rfe re 
wi th transdermal de li ve ry of the P LA2 inhibi tors. is unlikely 
beca use: (i) we empl oyed 10-fold higher concentratio ns o f lipid 
than inhibito r (1 / 10 vol) to avo id dilutio nal effects; and (ii) we 
showed that palmiti c acid reverses inhibi to r-induced abno rmalit ies 
in isolated stratum corn eum . after prio r uptake of the SC agen ts 
[15] . T hus, these and the ea rli er studies [15 .34] indica te that free 
fa tty acid s can res tore SC stru cture and fUll ctio n by inte racting 
directly w ithin the SC. 
C hronic trea tment wi th both BPB and MJ 33 also caused epider-
mal hyperpl asia. It is unlikely that th e epide rmal hyp erplas ia is due 
to an irritan t effect o r nonspecific toxicity of BPB o r MJ33, because 
these hi stologic changes could be preve nted by simul taneous 
topical trea tme nt w ith palmitic ;lcid . Several explana tio ns can be 
invoked to explain the develo pment of these alte ratio ns. O ur 
labora to ry has shown that barrier disrup tion stimulates epidermal 
DNA syn thesis [37] , and epidermal hyperpl asia is a prominen t 
fea ture of other experim ental m odels charac terized by a sustained 
barrie r de fect, such as essential fat ty acid dd i ciency [37] and 
chroni c lovastatin trea tmen t [38] . H owever, the h ypet-plasia in this 
mode l precedes the em ergence of the barrier abno rmali ty, and is 
reve rsibl e at these ea rly time po in ts b y fatty acid co- applicatio ns. 
Hence, o ur resul ts sugges t the alte rn ati ve possibili ty tha t PLA2 
inhjbi tion alo ne su ftices to pro du ce hyperplas ia, presllmably by 
modulation of P LA 2-induced signal tranduction e vents. 
In sum m ary. the presen t study provides evidence th at the 
extracellul ar catabo li sm of phospho Lipids to fatty acid s by PLA? is 
important fo r the fo rmation of normal SC lamellar b il aye rs and -fo r 
competent barrier fun ction . 
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39448, mill A R 39639; nffd lli e Medicol Rescnreli Sen'ice. Dcpnrlff ,"," ,!f r cfem ff s 
Affnirs. Ms. A ffgic Kli o-Kifff , M icli ie [lfIOffg, nffd j nso ff Kmpf pf'(l"ider/ ,·.wel/CIII 
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